Estimation of the level of macrophage migration inhibitory factor in patients with coronary artery disease in the presence of some risk factors
Background and objective: Coronary artery disease is a chronic inflammatory disease in which many risk factors and inflammatory mediators, including macrophage migration inhibitory factor, are involved. This study aimed to estimate macrophage migration inhibitory factor level in coronary artery disease patients in regard to age, gender, and smoking.
Methods: A total of 138 coronary artery disease patients and 38 coronary artery disease free control subjects were admitted to surgical specialty hospital-cardiac center in Erbil city, Iraq between January and December 2017. Plasma macrophage migration inhibitory factor concentration was measured by enzyme linked immunosorbent assay.
Results: Patients and controls were categorized into subgroups according to age (<55 and ≥55 years), gender (women and men), and smoking status (smokers and non-smokers). Macrophage migration inhibitory factor level in every coronary artery disease subgroup (age, gender, and smokers) patients increased significantly compared to the same control subgroups (P <0.05). Macrophage migration inhibitory factor level showed a higher level in coronary artery disease patients subgroups (≥55 years, female, smokers) compared to their corresponding coronary artery disease subgroups (<55 years, male, and non smokers). Macrophage migration inhibitory factor demonstrated a significant positive correlation with fibrinogen and high sensitivity C-reactive protein, insignificant positive correlation with age, total cholesterol, low density lipoprotein, and insignificant negative correlation with high density lipoprotein-cholesterol (P >0.05).
Conclusion: This study demonstrated the diagnostic value of macrophage migration inhibitory factor elevation in coronary artery disease patients if compared with coronary artery disease free subjects, meanwhile suggesting that age, gender, and smoking had no direct role in macrophage migration inhibitory factor elevation considering their secondary minor contributions in macrophage migration inhibitory factor circulation.
Galkina E, Ley K. Immune and Inflammatory Mechanisms of Atherosclerosis. Annu Rev Immuno 2009; 27:165–97.
Ganguli D, Das N, Saha I, Sanapala KR, Chaudhuri D, Ghosh S, et al. Association between inflammatory markers and cardiovascular risk factors in women from Kolkata, W.B, India. Arq Bras Cardiol 2011; 96(1):38–46.
El-Moselhy EA, Mohammed AS, Abd El-Aziz A, Sadek I, Hagrass SA, Farag GAS. Coronary artery disease among elderly Egyptian patients: I. Socio-demographic, lifestyle, psychosocial, medical, and biochemical risk factors. Am J Gerentol Geriatr 2018; 1(2):1006.
Bernhagen J, Krohn R, Lue H, Gregory JL, Zernecke A, Koenen RR, et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment, Nat Med 2007; 13(5):587–96.
Schober A, Bernhagen J, Thiele M, Zeiffer U, Knarren S, Roller M, et al. Stabilization of atherosclerotic plaques by blockade of macrophage migration inhibitory factor after vascular injury in apolipoprotein E-deficient. Circulation 2004; 109(3):380–5.
Müller II, Müller KA, Karathanos A, Schönleber H, Rath D, Vogel S, et al. Impact of counterbalance between macrophage migration inhibitory factor and its inhibitor Gremlin-1 in patients with coronary artery disease. Atherosclerosis 2014; 237(2):426–32.
Müller II, Müller KA, Schönleber H, Karathanos A, Schneider M, Jorbenadze R, et al. Macrophage migration inhibitory factor is enhanced in acute coronary syndromes and is associated with the inflammatory response. PloS One 2012; 7(6):e38376.
Chan W, White DA, Wang XY, Bai RF, Liu Y, Yu HY, et al. Macrophage migration inhibitory factor for the early prediction of infarct size. J Am Heart Assoc 2013; 2(5):e000226.
Zernecke A, Bernhagen J, Weber C. Macrophage migration inhibitory factor in cardiovascular disease. Circulation 2008; 117(12):1594–602.
Mendis S, Thygesen K, Kuulasmaa K, Giampaoli S, Mahonen M, Blackett KN, et al. World Health Organization definition of myocardial infarction: 2008-09 revision. Int J Epidemiol 2011; 40(1):139–46.
Ismael MK, Al-haleem MR, Salman RS. Evaluation of anti-Helicobacter pylori antibodies in a group of iraqi patients with atherosclerosis and coronary artery disease. Iraqi Journal of Science 2015; 56(1):81–8.
Albarzani MA. Angiographic profile in diabetic and non-diabetic patients with coronary artery disease in the Cardiac Specialty Hospital–Cardiac Center, Erbil, Iraq, Zanco Journal of Medical Sciences 2017; 21(2):1701–7.
Akcılar R, Yümün G, Bayat Z, Donbaloğlu O, Erselcan K, Ece E, et al. APJ receptor A445C gene polymorphism in Turkish patients with coronary artery disease. Int J Clin Exp Med 2015; 8(10):18793–9.
Razban MM, Eslami M, Bagherzadeh A. The relationship between serum levels of hs-CRP and coronary lesion severity. Clujul Med 2016; 89(3):322–6.
vanDiepen JA, Berbée JF, Havekes LM, Rensen PC. Interactions between inflammation and lipid metabolism_ relevance for efficacy of anti-inflammatory drugs in the treatment of atherosclerosis. Atherosclerosis 2013; 228(2):306–15.
Hao Y, Yi SL, Zhong JQ. Serum macrophage migration inhibitory factor levels are associated with angiographically complex coronary lesions in patients with coronary artery disease. Genet Test Mol Biomarkers 2015; 19(10):556–60.
Qian L, Wang XY, Thapa S, Tao LY, Wu SZ, Luo GJ, et al. Macrophage migration inhibitory factor promoter polymorphisms (-794 CATT5-8): Relationship with soluble MIF levels in coronary atherosclerotic disease subjects. BMC Cardiovasc Disord 2017;17(1):144.
Noels H, Bernhagen J, Weber C. Macrophage migration inhibitory factor_ a noncanonical chemokine important in atherosclerosis. Trends Cardiovasc Med 2009; 19(3):76–86.
Simons D, Grieb G, Hristov M, Pallua, N, Weber C, Bernhagen J, et al. Hypoxia-induced endothelial secretion of macrophage migration inhibitory factor and role in endothelial progenitor cell recruitment. J Cell Mol Med 2011; 15(3):668–78.
Jian Z, Li JB, Ma RY, Chen L, Zhong QJ, Wang XF, et al. Increase of macrophage migration inhibitory factor (MIF) expression in cardiomyocytes during chronic hypoxia. Clin Chim Acta 2009; 405(1–2):132–8.
Redondo S, Santos-Gallego CG, Ganado P, García M, Rico L, Del Rio M, et al. Acetylsalicylic acid inhibits cell proliferation by involving transforming growth factor-β. Circulation 2003; 107(4):626–9.
Diamantis E, Kyriakos G, Quiles-Sanchez LV, Farmaki P, Troupis T. The anti-inflammatory effects of statins on coronary artery disease: An updated review of the literature. Curr Cardiol Rev 2017; 13(3):209–16.
Boekholdt SM, Peters RJ, Day NE, Luben R, Bingham SA, Wareham NJ, et al. Macrophage migration inhibitory factor and the risk of myocardial infarction or death due to coronary artery disease in adults without prior myocardial infarction or stroke: The EPIC-Norfolk prospective population study. Am J Med 2004; 117(6):390–7.
Herder C, Illig T, Baumert J, Müller M, Klopp N, Khuseyinova N, et al. Macrophage migration inhibitory factor (MIF) and risk for coronary heart disease: Results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Atherosclerosis 2008; 200(2):380–8.
Ji K, Wang X, Li J, Lu Q, Wang G, Xue Y, et al. Macrophage migration inhibitory factor polymorphism is associated with susceptibility to inflammatory coronary heart disease. Bio Med Research International 2015; 2015:315174.
Luo JY, Xu R, Li XM, Zhou Y, Zhao Q, Liu F, et al. MIF gene polymorphism rs755622 is associated with coronary artery disease and severity of coronary lesions in a Chinese Kazakh population: A case-control study. Medicine (Baltimore) 2016; 95(4):e2617.
Hardman MJ, Waite A, Zeef L, Burow M, Nakayama T, Ashcroft GS. Macrophage migration inhibitory factor: A central regulator of wound healing. Am J Pathol 2005; 167(6):1561–74.
Pathak LA, Shirodkar S, Ruparelia R, Rajebahadur J. Coronary artery disease in women. Indian Heart J 2017; 69(4):532–8.
Papathanasiou G, Mamali A, Papafloratos S, Zerva E. Effects of smoking on cardiovascular function: The role of nicotine and carbon monoxide. Health Science Journal 2014; 8(2):274–90.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The copyright on any article published in Zanco J Med Sci is retained by the author(s) in agreement with the Creative Commons Attribution Non-Commercial ShareAlike License (CC BY-NC-SA 4.0).